Early therapeutics development with phase II emphasis

Ended Definitive Contract Awarded Last action

Contract number
HHSN261200622009C
Awardee
Awarding agency
Obligated
$5,730,108

Award facts

Opportunity
  • N01CM5701816 Solicitation number
Contract value 17% obligated
  • $23,835,737.26 Current, with exercised options
  • $34,176,737.26 Potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
Not on record
Set-aside
No set-aside
Competition
Full and Open Competition · 11 offers Negotiated Proposal / Quote
Pricing
Cost No Fee
Place of performance
Davis, CA, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Change Order 21 -$29,644
Change Order 20 -$190,106
Other Administrative Action 19 · To extend the arra portion of this contract through 12/31/2013 $0
Other Administrative Action 18 · Final_close_process - -$73,513
Other Administrative Action 17 · Other functions the purpose of this modification is to obligate prior year (FY11) funds to accommodate prior accruals. $0
Funding Only Action 16 · The purpose of this modification is to obligate prior year (FY11) funds to accommodate prior accruals. $208,888
Other Administrative Action 15 · The purpose of this modification is to extend the arra portion of this contract through june 30, 2013. $0
Funding Only Action 14 $103,410
Funding Only Action 13 $165,456
Funding Only Action 12 $356,380
Funding Only Action 11 $179,284
Other Administrative Action 10 $103,410
Exercise an Option 9 $146,842
Funding Only Action 8 · Biomedical (basic) $71,623
Funding Only Action 7 · Recovery act - actnow clinical trial 8155 under "early therapeutics development with phase II emphasis" arra::yes::arra $942,533
Exercise an Option 6 $32,000
Other Administrative Action 5 $880,592
Funding Only Action 4 $995,559
Funding Only Action 3 $318,394
Funding Only Action 2 $550,028
Funding Only Action 1 $107,222
Original award $861,750
Show all 22

About this award

Written by GovTribe AI ·

This is a federal contract award from the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to the University of California, Davis (UC Davis) for early-stage therapeutic development with a focus on Phase II clinical trials. The $34,176,737.26 definitive cost-reimbursement contract was awarded on January 1, 2006 with a period of performance through February 20, 2015. The contract did not have a small business set-aside. UC Davis, a major public research university, frequently receives federal research awards and provides specialized scientific and technical services to agencies across the government. This award likely supports the NCI's mission to conduct and support cancer research, as UC Davis has deep expertise in biomedical sciences, oncology, and related disciplines. The contract provides the government with access to UC Davis's research infrastructure and scientific capabilities to advance the development of new cancer treatments.

Quick answers

Who was awarded contract HHSN261200622009C?

HHSN261200622009C was awarded to University Of California, Davis by National Cancer Institute (National Institutes of Health) on January 1, 2006.

How much is contract HHSN261200622009C worth?

The government has obligated $5,730,108 on HHSN261200622009C. Its current value, with exercised options, is $23,835,737. Its potential value, with all options, is $34,176,737.

Was contract HHSN261200622009C competed?

The extent of competition for HHSN261200622009C was full and open competition. The government received 11 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login